<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    11791949
   </pmid>
   <datecreated>
    <year>
     2002
    </year>
    <month>
     01
    </month>
    <day>
     15
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2002
    </year>
    <month>
     04
    </month>
    <day>
     05
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      1040-1237
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       13
      </volume>
      <issue>
       3
      </issue>
      <pubdate>
       <year>
        2001
       </year>
       <month>
        Sep
       </month>
      </pubdate>
     </journalissue>
     <title>
      Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
     </title>
     <isoabbreviation>
      Ann Clin Psychiatry
     </isoabbreviation>
    </journal>
    <articletitle>
     Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults.
    </articletitle>
    <pagination>
     <medlinepgn>
      129-34
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      Despite the increasing recognition of attention-deficit hyperactivity disorder (ADHD) in adults, there are few controlled trials demonstrating the effectiveness of pharmacological treatments, particularly with nonstimulants. One controlled trial found bupropion SR more effective than placebo in the treatment of ADHD adults. We conducted a controlled study to contrast the effectiveness of bupropion SR and methylphenidate to placebo in ADHD adults. A randomized, double-blind, parallel design was used in this study. Following a 7-day placebo lead-in, 30 ADHD (DSM-IV) subjects (18-60 years old) were randomized to bupropion, methylphenidate, or placebo for 7 weeks. Methylphenidate was titrated over 1 week to a maximum dose of 0.9 mg/kg/d divided into 3 doses while bupropion was titrated over 2 weeks to a maximum dose of 200 mg A.M. and 100 mg P.M. Response rates based on Clinical Global Impression improvement ratings in patients receiving bupropion, methylphenidate, and placebo were 64, 50, and 27%, respectively. The difference in response rates between active treatment and placebo was not statistically significant (p = 0.14). Neuropsychological testing demonstrated trends favoring drug treatment on measures of immediate recall and verbal fluency. While bupropion SR may be a viable clinical alternative for adults with ADHD, further investigation is needed.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Psychiatry, College of Medicine, University of Iowa, Iowa City 52242, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Kuperman
      </lastname>
      <forename>
       S
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Perry
      </lastname>
      <forename>
       P J
      </forename>
      <initials>
       PJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Gaffney
      </lastname>
      <forename>
       G R
      </forename>
      <initials>
       GR
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lund
      </lastname>
      <forename>
       B C
      </forename>
      <initials>
       BC
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Bever-Stille
      </lastname>
      <forename>
       K A
      </forename>
      <initials>
       KA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Arndt
      </lastname>
      <forename>
       S
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Holman
      </lastname>
      <forename>
       T L
      </forename>
      <initials>
       TL
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Moser
      </lastname>
      <forename>
       D J
      </forename>
      <initials>
       DJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Paulsen
      </lastname>
      <forename>
       J S
      </forename>
      <initials>
       JS
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Ann Clin Psychiatry
    </medlineta>
    <nlmuniqueid>
     8911021
    </nlmuniqueid>
    <issnlinking>
     1040-1237
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Adrenergic Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Dopamine Uptake Inhibitors
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      113-45-1
     </registrynumber>
     <nameofsubstance>
      Methylphenidate
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      34841-39-9
     </registrynumber>
     <nameofsubstance>
      Bupropion
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adrenergic Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Attention Deficit Disorder with Hyperactivity
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      psychology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bupropion
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Dopamine Uptake Inhibitors
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Methylphenidate
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Neuropsychological Tests
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Severity of Illness Index
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Time Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2002
     </year>
     <month>
      1
     </month>
     <day>
      17
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2002
     </year>
     <month>
      4
     </month>
     <day>
      6
     </day>
     <hour>
      10
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2002
     </year>
     <month>
      1
     </month>
     <day>
      17
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     11791949
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

